Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30292889 | 1.00 | HRH3 (0.44) | HRH3CYP1A2CYP2D6PPARGRXRA | |
| SCHEMBL25909219 | 0.86 | HRH3 (0.40) | HRH3CYP1A2CYP2D6RXRAPSMD10 | |
| SCHEMBL2881272 | 0.83 | PSMD10 (0.38) | PSMD10CA1CA9CA12HPGD | |
| SCHEMBL932051 | 0.83 | HTR2A (0.44) | PSMD10CA1CA9CA12HTR2A | |
| SCHEMBL1162383 | 0.80 | HRH3 (0.47) | HRH3CYP1A2CYP2D6PPARGRXRA | |
| SCHEMBL121411 | 0.80 | CA1 (0.40) | PSMD10CA1CA9CA12ALDH1A1 | |
| SCHEMBL17023777 | 0.78 | CA1 (0.39) | PSMD10CA1CA9CA12ALDH1A1 | |
| SCHEMBL18289524 | 0.78 | CA1 (0.50) | CYP3A4CA1CA9CA12ALDH1A1 | |
| SCHEMBL6906905 | 0.78 | CA1 (0.50) | CYP3A4CA1CA9CA12ALDH1A1 | |
| SCHEMBL26338334 | 0.78 | UCHL1 (0.44) | PSMD10CA1CA9CA12HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009148195-A1 | 5-(4-HYDROXYBENZYL)THIAZOLIDINE-2,4-DIONE AS INTERMEDIATE FOR SYNTHESIS OF THIAZOLIDINEDIONE BASED COMPOUNDS AND PROCESS FOR PREPARING THE SAME | DAEBONG LS, LTD. (KR) | 2009-12-10 | — | — | WO | claimed |
| US-9701635-B2 | C-H fluorination of heterocycles with silver (II) fluoride | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701635-B2 | C-H fluorination of heterocycles with silver (II) fluoride | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160185723-A1 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-30 | — | — | US | disclosed |
| US-20160185723-A1 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-30 | — | — | US | disclosed |
| WO-2015013715-A2 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | THR REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2015013715-A2 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | THR REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2009148195-A1 | 5-(4-HYDROXYBENZYL)THIAZOLIDINE-2,4-DIONE AS INTERMEDIATE FOR SYNTHESIS OF THIAZOLIDINEDIONE BASED COMPOUNDS AND PROCESS FOR PREPARING THE SAME | DAEBONG LS, LTD. (KR) | 2009-12-10 | — | — | WO | disclosed |
| EP-1387843-B1 | METHOD FOR OBTAINING PIOGLITAZONE AS AN ANTIDIABETIC AGENT | ZENTIVA AS (CZ) | 2007-02-28 | — | — | EP | disclosed |
| US-7009057-B2 | Method for obtaining pioglitazone as an antidiabetic agent | ZENTIVA A.S. (CZ) | 2006-03-07 | — | — | US | disclosed |
| WO-2004108721-A1 | PROCESS FOR THE PREPARATION OF 5-[[4-[2-(5-ETHYL-2-PYRIDINYL)ETHOXY]PHENYL] METHYL]-2,4-THIAZOLIDINEDIONE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2004-12-16 | — | — | WO | disclosed |
| EP-1387843-A1 | METHOD FOR OBTAINING PIOGLITAZONE AS AN ANTIDIABETIC AGENT | Leciva, A.S. (CZ) | 2004-02-11 | — | — | EP | disclosed |
| EP-0816340-B1 | Process for preparing 4-(2-(2-pyridyl)ethoxy)benzaldehyde derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002088120-A1 | METHOD FOR OBTAINING PIOGLITAZONE AS AN ANTIDIABETIC AGENT | Léciva, a.s. (CZ) | 2002-11-07 | — | — | WO | disclosed |
| US-6100403-A | Production of benzaldehyde compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-08 | — | — | US | disclosed |
| US-5952509-A | REACTING P-HYDROXYBENZALDEHYDE WITH A PYRIDYL-ETHYL SULFONATE DERIVATIVE TO FORM 4-(2-(SUBSTITUTED OR NONSUBSTITUTED-2-PYRIDYL)ETHOXY) BENZALDEHYDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0816340-A1 | Process for preparing 4-(2-(2-pyridyl)ethoxy)benzaldehyde derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
| US-5554758-A | Method for producing ethers | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-10 | — | — | US | disclosed |
| EP-0506273-B1 | Method for producing ethers | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-05-31 | — | — | EP | disclosed |
| EP-0506273-A2 | Method for producing ethers | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185723-A1 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | AFF2, INF2, NPFFR2 | HRH3 23/4885CYP1A2 39/4885CYP2D6 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.